
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    1. Key functional markers and pathways<br><br>I‚Äôll first group the most informative genes by function, with emphasis on brain myeloid biology.<br><br>**a. Complement, innate immune activation, opsonization**<br>- **C1QA, C1QB, C1QC** ‚Äì Classical complement pathway components; hallmark of microglia and CNS macrophages, especially activated/disease-associated states.<br>- **C3** ‚Äì Central complement component; upregulated in inflammatory/activated microglia and macrophages.<br>- **FCGR3A (CD16)** ‚Äì FcŒ≥ receptor III; mediates antibody-dependent phagocytosis, typical of activated/‚Äúnon-homeostatic‚Äù microglia and perivascular macrophages.<br>- **FCER1G** ‚Äì Fc receptor Œ≥ chain; signaling adaptor for multiple Fc receptors, associated with phagocytic myeloid cells.<br>- **VSIG4** ‚Äì Complement receptor of the immunoglobulin superfamily; expressed by tissue macrophages, including CNS border-associated macrophages, with roles in complement regulation and immune suppression.<br><br>**b. Antigen presentation / MHC-II**<br>- **HLA-DRA, HLA-DRB1, HLA-DRB5, HLA-DPA1, HLA-DPB1, HLA-DQA1, CD74** ‚Äì MHC class II molecules and invariant chain; strong signature of professional antigen-presenting myeloid cells (microglia, macrophages, dendritic cells). In brain, high MHC-II is characteristic of activated microglia and border-associated macrophages.<br>- **TMEM176A, TMEM176B** ‚Äì Associated with antigen-presenting cells and MHC-II+ myeloid populations; often upregulated in activated myeloid cells.<br><br>**c. Inflammatory cytokines / chemokines / acute response**<br>- **IL1A, IL1B, TNF** ‚Äì Canonical pro-inflammatory cytokines; hallmark of activated, inflammatory myeloid cells.<br>- **CCL3, CCL3L1, CCL20** ‚Äì Pro-inflammatory chemokines; CCL3/CCL3L1 recruit monocytes and T cells; CCL20 is associated with Th17 recruitment and mucosal-type inflammation but also seen in activated myeloid cells.<br>- **S100A8, S100A9** ‚Äì Calcium-binding proteins; strong markers of inflammatory myeloid cells, especially infiltrating monocytes/neutrophil-like states, but can appear in highly activated microglia/macrophages.<br>- **BCL2A1** ‚Äì Anti-apoptotic gene induced by NF-Œ∫B; often upregulated in activated inflammatory myeloid cells.<br>- **G0S2** ‚Äì Cell cycle/activation-associated; often induced in activated immune cells.<br><br>**d. Phagocytosis, lysosomal, myeloid core**<br>- **AIF1 (IBA1)** ‚Äì Classic microglia/macrophage marker; actin-binding protein involved in motility and phagocytosis.<br>- **TYROBP (DAP12)** ‚Äì Signaling adaptor for multiple microglial receptors (e.g., TREM2, SIRPŒ≤); central to microglial activation and DAM (disease-associated microglia) programs.<br>- **TREM2** ‚Äì Microglia-enriched receptor; key in DAM/activated microglia, lipid sensing, phagocytosis.<br>- **CD68** ‚Äì Lysosomal glycoprotein; pan-macrophage/microglia marker, enriched in phagocytic/activated states.<br>- **LAPTM5** ‚Äì Lysosomal protein; broadly expressed in myeloid/lymphoid cells, associated with phagolysosomal function.<br>- **LY96 (MD-2), LY86 (MD-1)** ‚Äì Co-receptors in TLR signaling complexes; innate immune activation.<br>- **ALOX5AP** ‚Äì 5-lipoxygenase-activating protein; leukotriene biosynthesis, typical of myeloid inflammatory cells.<br>- **F13A1** ‚Äì Coagulation factor XIII A chain; enriched in tissue macrophages and some microglial states.<br>- **RNASE2** ‚Äì Secreted ribonuclease; often in myeloid cells with inflammatory/antimicrobial roles.<br><br>**e. Lipid handling, metabolism, tissue-resident macrophage features**<br>- **APOC1** ‚Äì Apolipoprotein C1; strongly upregulated in lipid-associated microglia/macrophages (DAM/LAM) and border-associated macrophages.<br>- **SPP1 (osteopontin)** ‚Äì Secreted glycoprotein; hallmark of SPP1+ activated microglia/macrophages in neuroinflammation, neurodegeneration, and perivascular macrophages.<br>- **FOLR2** ‚Äì Folate receptor Œ≤; classic marker of tissue-resident macrophages (including perivascular and meningeal macrophages) and some anti-inflammatory macrophage states.<br>- **HPGDS** ‚Äì Hematopoietic prostaglandin D synthase; enriched in certain macrophage subsets (including meningeal/perivascular macrophages) and some microglial states.<br>- **HAMP (hepcidin)** ‚Äì Iron-regulatory hormone; expressed by macrophages in iron handling and inflammatory contexts.<br>- **FTL** ‚Äì Ferritin light chain; iron storage, often high in macrophages and microglia with iron handling/oxidative stress.<br><br>**f. Other myeloid / immune markers**<br>- **CD14** ‚Äì Co-receptor for LPS; classical monocyte/macrophage marker, also upregulated in activated microglia.<br>- **MS4A4A, MS4A6A** ‚Äì MS4A family; MS4A6A is a well-known microglial gene; MS4A4A is expressed in macrophages and some microglial subsets.<br>- **GPR34** ‚Äì G protein‚Äìcoupled receptor; enriched in microglia and CNS macrophages.<br>- **TMIGD3** ‚Äì Less characterized; reported in myeloid/immune contexts.<br>- **FCGBP** ‚Äì Fc fragment of IgG binding protein; mucosal/immune-related, but can appear in activated myeloid cells.<br>- **NPL** ‚Äì N-acetylneuraminate pyruvate lyase; metabolic enzyme, sometimes enriched in myeloid cells.<br>- **SCIN** ‚Äì Scinderin; actin-severing protein, can be upregulated in activated immune cells.<br><br>2. Key cell type markers (tissue/cell identity)<br><br>From the above, the dominant identity markers are:<br><br>**Microglia / CNS macrophage core**<br>- **C1QA/B/C** ‚Äì Canonical microglia and CNS macrophage markers.<br>- **AIF1 (IBA1)** ‚Äì Pan-microglia/macrophage in CNS.<br>- **TYROBP, TREM2** ‚Äì Strongly associated with microglia, especially DAM/activated states.<br>- **MS4A6A, GPR34** ‚Äì Microglia-enriched genes in human brain datasets.<br>- **APOC1, SPP1** ‚Äì Prominent in disease-associated/activated microglia and perivascular/meningeal macrophages.<br>- **CD68, LAPTM5, FCER1G, FCGR3A, VSIG4, FOLR2, HPGDS** ‚Äì Tissue-resident macrophage / CNS border-associated macrophage markers.<br><br>**Antigen-presenting myeloid cells**<br>- **HLA-DRA/DRB1/DRB5/DPA1/DPB1/DQA1, CD74, TMEM176A/B** ‚Äì Strong MHC-II+ antigen-presenting myeloid signature, typical of activated microglia and CNS border macrophages, less so for homeostatic microglia.<br><br>**Inflammatory myeloid / monocyte-like features**<br>- **IL1A, IL1B, TNF, CCL3, CCL3L1, CCL20, S100A8, S100A9, BCL2A1, RNASE2, ALOX5AP, CD14** ‚Äì Strong inflammatory myeloid/monocyte-like program, suggesting a non-homeostatic, activated state.<br><br>3. Cross-referencing with known scRNA-seq brain atlases<br><br>Comparing this signature to major human brain scRNA-seq references:<br><br>- **Human microglia atlases (e.g., Olah et al. 2020, Sankowski et al. 2019, Masuda et al. 2019, Keren-Shaul et al. 2017 for DAM in mouse)**:<br>  - **C1QA/B/C, APOC1, SPP1, TREM2, TYROBP, MS4A6A, GPR34, HLA-DRA/B, CD74, FCGR3A, FCER1G, CD68** are characteristic of **activated/DAM-like microglia**.<br>  - **SPP1+ / APOC1+ / TREM2+ / C1Q+** clusters are repeatedly annotated as **SPP1+ disease-associated microglia** or **lipid-associated microglia** in neurodegenerative and inflammatory conditions.<br>  - **S100A8/A9, CCL3, IL1B, TNF** are often enriched in **inflammatory microglia** or **infiltrating monocyte-derived macrophages**, depending on context.<br><br>- **CNS border-associated macrophages (perivascular, meningeal, choroid plexus) (e.g., Van Hove et al. 2019; Utz et al. 2020; Jord√£o et al. 2019)**:<br>  - **FOLR2, VSIG4, HPGDS, APOC1, C1QA/B/C, HLA-II, SPP1** are typical of **perivascular/meningeal macrophages**.<br>  - These cells are strongly MHC-II+, complement-high, and often SPP1+.<br><br>- **Peripheral monocytes/macrophages**:<br>  - **S100A8/A9, RNASE2, CCL3, CCL20, CD14, FCGR3A** are common in **classical/intermediate monocytes** and **inflammatory macrophages**.<br>  - However, the strong presence of **GPR34, MS4A6A, TREM2, TYROBP, C1Q genes** and the brain context strongly favor **CNS-resident microglia/macrophages** rather than circulating monocytes.<br><br>Overall, the profile matches **CNS myeloid cells** with a **highly activated, inflammatory, and antigen-presenting phenotype**, overlapping with **SPP1+/APOC1+/TREM2+ disease-associated microglia** and **perivascular/meningeal macrophages**.<br><br>4. Most probable general cell type<br><br>Given:<br>- Strong microglial core (C1Q, AIF1, TYROBP, TREM2, MS4A6A, GPR34).<br>- Strong tissue-resident macrophage/border-associated markers (FOLR2, VSIG4, HPGDS, APOC1, SPP1).<br>- Strong MHC-II and inflammatory cytokine expression.<br><br>The most probable **general cell type** is:<br><br>**CNS myeloid cell: activated microglia / CNS macrophage (including border-associated macrophages).**<br><br>5. Top 3 most probable sub cell types (ranked)<br><br>Now refine within CNS myeloid lineages:<br><br>### 1) SPP1+/APOC1+/TREM2+ disease-associated / activated microglia  <br>**Evidence:**<br>- **Microglia core:** C1QA/B/C, AIF1, TYROBP, TREM2, MS4A6A, GPR34.<br>- **DAM/activated markers:** SPP1, APOC1, TREM2, TYROBP, C1Q genes, APOC1, FCGR3A, FCER1G.<br>- **Inflammatory cytokines:** IL1A, IL1B, TNF, CCL3, CCL3L1, CCL20.<br>- **MHC-II high:** HLA-DRA/DRB1/DRB5/DPA1/DPB1/DQA1, CD74, TMEM176A/B.<br>- **Lipid/iron handling:** APOC1, HAMP, FTL, ALOX5AP, F13A1.<br><br>This combination is highly characteristic of **SPP1+ disease-associated microglia** described in human neurodegenerative and inflammatory brain conditions: microglia that are **TREM2/TYROBP-driven, complement-high, MHC-II+, and SPP1/APOC1+**.<br><br>### 2) Perivascular / meningeal (border-associated) macrophages  <br>**Evidence:**<br>- **Border-associated markers:** FOLR2, VSIG4, HPGDS, APOC1, C1QA/B/C, HLA-II, SPP1.<br>- These cells are typically **MHC-II high, complement-high, SPP1+**, and express **FOLR2 and VSIG4**, which are classic tissue-resident macrophage markers.<br>- However, some of these markers overlap with DAM-like microglia, and the presence of strong microglia-enriched genes (GPR34, MS4A6A, TREM2) slightly favors microglia over pure border macrophages.<br><br>Thus, a substantial fraction of this signature could also correspond to **perivascular/meningeal macrophages**, especially if the dataset includes leptomeninges or vascular compartments.<br><br>### 3) Infiltrating inflammatory monocyte-derived macrophages (brain-infiltrating myeloid cells)  <br>**Evidence:**<br>- **Monocyte-like inflammatory markers:** S100A8, S100A9, RNASE2, CCL3, CCL20, CD14, FCGR3A, BCL2A1.<br>- These are typical of **classical/intermediate monocytes** and **inflammatory macrophages**.<br>- However, the strong expression of **microglia-enriched genes (GPR34, MS4A6A, TREM2, C1Q)** and the presence of **FOLR2/VSIG4/HPGDS** argue that the cluster is not purely infiltrating monocytes but more aligned with CNS-resident myeloid cells.<br><br>So infiltrating monocyte-derived macrophages are a plausible but less likely annotation than DAM-like microglia or border-associated macrophages.<br><br>**Most likely subtype:**<br>- **Primary annotation:** **SPP1+/APOC1+/TREM2+ disease-associated / activated microglia (MHC-II high, inflammatory microglia).**<br><br>If you need a concise label for downstream use, something like:<br><br>> ‚ÄúActivated/DAM-like microglia (SPP1+/APOC1+/TREM2+, MHC-II+)‚Äù<br><br>would be appropriate.<br><br>6. Concise summary<br><br>- The marker set is dominated by **microglial/CNS macrophage genes** (C1QA/B/C, AIF1, TYROBP, TREM2, MS4A6A, GPR34) with strong **MHC-II** (HLA-DRA/DRB1/DRB5/DPA1/DPB1/DQA1, CD74) and **inflammatory cytokine/chemokine** expression (IL1A, IL1B, TNF, CCL3, CCL3L1, CCL20).<br>- **SPP1, APOC1, TREM2, TYROBP, C1Q, FCGR3A, FCER1G** define a **disease-associated/activated microglia** program, while **FOLR2, VSIG4, HPGDS** point toward **tissue-resident CNS macrophages (border-associated)**.<br>- The best overall interpretation is a cluster of **activated, SPP1+/APOC1+/TREM2+ disease-associated microglia**, with some overlap with **perivascular/meningeal macrophage** signatures and inflammatory monocyte-like features.<br><br>**FINAL ANNOTATION COMPLETED**
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">CNS myeloid cell: activated/DAM-like microglia or CNS macrophage</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>SPP1+/APOC1+/TREM2+ disease-associated / activated microglia (MHC-II high, inflammatory microglia)</li><li>Perivascular / meningeal (border-associated) macrophages</li><li>Infiltrating inflammatory monocyte-derived macrophages (brain-infiltrating myeloid cells)</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Activated/DAM-like microglia mixed with perivascular/meningeal (border-associated) macrophages</li><li>CNS-resident microglia/macrophages with infiltrating inflammatory monocyte-derived macrophage features</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">nan</div>
                        <div class="scoring-content">
                            Error: Error code: 400 - {'error': {'message': "Unsupported parameter: 'max_tokens' is not supported with this model. Use 'max_completion_tokens' instead.", 'type': 'invalid_request_error', 'param': 'max_tokens', 'code': 'unsupported_parameter'}}<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    